Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sanofi India's share price for the quarter that ended in Mar. 2026 was ₹3207. Sanofi India's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 23 Mil. Therefore, Sanofi India's market cap for the quarter that ended in Mar. 2026 was ₹73,860 Mil.
Sanofi India's quarterly market cap
declined
from Sep. 2025 (₹107,114 Mil) to Dec. 2025 (₹94,236 Mil) and
declined
from Dec. 2025 (₹94,236 Mil) to Mar. 2026 (₹73,860 Mil).
Sanofi India's annual market cap
increased
from Dec. 2023 (₹102,866 Mil) to Dec. 2024 (₹140,972 Mil) but then
declined
from Dec. 2024 (₹140,972 Mil) to Dec. 2025 (₹94,236 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sanofi India's Enterprise Value for Today is ₹75,145 Mil.
Sanofi India (BOM:500674) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sanofi India Market Cap Related Terms
Sanofi India Market Cap Historical Data
* Premium members only.
The historical data trend for Sanofi India's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500674 vs LLY, JNJ, ABBV: Market Cap Comparison
For the Drug Manufacturers - General subindustry, Sanofi India's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi India Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi India's Market Cap distribution charts can be found below:
* The bar in red indicates where Sanofi India's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sanofi India's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi India (BOM:500674) has a Market Cap of ₹77,596 Mil as of Jul. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sanofi India and its competitors. According to the industry distribution chart, Sanofi India ranks #302 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 29.5%.
Is Sanofi India's Market Cap too high?
Sanofi India's current Market Cap is ₹77,596 Mil. Based on the distribution chart, Sanofi India ranks #302 out of 1024 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sanofi India has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi India's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi India ranks #302 out of 1024 companies for Market Cap. This puts Sanofi India in the upper half of its industry. The industry median Market Cap is 208.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 208.62, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sanofi India and its competitors. For the Drug Manufacturers industry, the median Market Cap is 208.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi India's current Market Cap is ₹77,596 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi India stock overvalued right now?
Based on GuruFocus' analysis, Sanofi India (BOM:500674) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹4,402.68, compared to a current price of ₹3,369.25 — trading 23.5% below its estimated fair value. The current Market Cap is ₹77,596 Mil. Sanofi India's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sanofi India (BOM:500674), the current Market Cap is ₹77,596 Mil as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanofi India (BOM:500674) Overvalued in 2026?
Based on GuruFocus' analysis, Sanofi India stock appears to be undervalued.
The current stock price of ₹3,369.25 is trading 23.5% below its estimated GF Value™ of ₹4,402.68.
GuruFocus considers Sanofi India to be Modestly Undervalued.
Key valuation signals for BOM:500674:
Market Cap: ₹77,596 Mil
GF Value™: ₹4,402.68 vs. price of ₹3,369.25 (23.5% below fair value)
No single metric tells the full story. See the BOM:500674 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and Other markets.
77GF Score
Get the complete analysis for BOM:500674
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500674 has been successfully added to your 
